Treatment Efficacy Rankings

📖 Wiki Page

therapeutic1103 wordssynced 2026-04-02

Treatment Efficacy Rankings

Overview

...

Treatment Efficacy Rankings

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Treatment Efficacy Rankings</th>
</tr>
<tr>
<td class="label">Rank</td>
<td>Treatment</td>
</tr>
<tr>
<td class="label">1</td>
<td>[Lecanemab](/therapeutics/lecanemab)</td>
</tr>
<tr>
<td class="label">2</td>
<td>[Donanemab](/therapeutics/donanemab)</td>
</tr>
<tr>
<td class="label">3</td>
<td>[Aducanumab](/therapeutics/aducanumab)</td>
</tr>
<tr>
<td class="label">4</td>
<td>[Atabecestat](/therapeutics/atabecestat)</td>
</tr>
<tr>
<td class="label">Rank</td>
<td>Treatment</td>
</tr>
<tr>
<td class="label">1</td>
<td>[Donepezil](/therapeutics/donepezil)</td>
</tr>
<tr>
<td class="label">2</td>
<td>[Memantine](/therapeutics/memantine)</td>
</tr>
<tr>
<td class="label">3</td>
<td>[Rivastigmine](/therapeutics/rivastigmine)</td>
</tr>
<tr>
<td class="label">Rank</td>
<td>Treatment</td>
</tr>
<tr>
<td class="label">1</td>
<td>[Levodopa/Carbidopa](/therapeutics/levodopa)</td>
</tr>
<tr>
<td class="label">2</td>
<td>[Deep Brain Stimulation](/therapeutics/deep-brain-stimulation)</td>
</tr>
<tr>
<td class="label">3</td>
<td>[ Pramipexole](/therapeutics/pramipexole)</td>
</tr>
<tr>
<td class="label">Rank</td>
<td>Treatment</td>
</tr>
<tr>
<td class="label">1</td>
<td>[Inosine](/therapeutics/inosine)</td>
</tr>
<tr>
<td class="label">2</td>
<td>[GM1 ganglioside](/therapeutics/gm1-ganglioside)</td>
</tr>
<tr>
<td class="label">Rank</td>
<td>Treatment</td>
</tr>
<tr>
<td class="label">1</td>
<td>[Tofersen](/therapeutics/tofersen)</td>
</tr>
<tr>
<td class="label">2</td>
<td>[Riluzole](/therapeutics/riluzole)</td>
</tr>
<tr>
<td class="label">3</td>
<td>[Edaravone](/therapeutics/edaravone)</td>
</tr>
<tr>
<td class="label">4</td>
<td>[Relyvrio](/therapeutics/relyvrio)</td>
</tr>
<tr>
<td class="label">Rank</td>
<td>Treatment</td>
</tr>
<tr>
<td class="label">1</td>
<td>[Tetrabenazine](/therapeutics/tetrabenazine)</td>
</tr>
<tr>
<td class="label">2</td>
<td>[Deutetrabenazine](/therapeutics/deutetrabenazine)</td>
</tr>
<tr>
<td class="label">3</td>
<td>[Tominersen](/therapeutics/tominersen)</td>
</tr>
<tr>
<td class="label">Rank</td>
<td>Treatment</td>
</tr>
<tr>
<td class="label">1</td>
<td>Structured exercise (aerobic + resistance + balance)</td>
</tr>
<tr>
<td class="label">2</td>
<td>Mediterranean/MIND diet</td>
</tr>
<tr>
<td class="label">3</td>
<td>Multidisciplinary rehabilitation (PT/OT/SLP)</td>
</tr>
<tr>
<td class="label">4</td>
<td>Rasagiline (MAO-B inhibitor)</td>
</tr>
<tr>
<td class="label">5</td>
<td>Rapamycin (mTOR inhibition)</td>
</tr>
<tr>
<td class="label">6</td>
<td>TUDCA/UDCA (bile acid therapy)</td>
</tr>
<tr>
<td class="label">7</td>
<td>Vitamin D supplementation</td>
</tr>
<tr>
<td class="label">8</td>
<td>Spermidine (autophagy induction)</td>
</tr>
<tr>
<td class="label">9</td>
<td>Photobiomodulation (PBM)</td>
</tr>
<tr>
<td class="label">10</td>
<td>Cognitive reserve/mental engagement</td>
</tr>
<tr>
<td class="label">Rank</td>
<td>Treatment</td>
</tr>
<tr>
<td class="label">11</td>
<td>Resveratrol/SIRT1 activation</td>
</tr>
<tr>
<td class="label">12</td>
<td>Creatine supplementation</td>
</tr>
<tr>
<td class="label">13</td>
<td>Methylene Blue/LMTX</td>
</tr>
<tr>
<td class="label">14</td>
<td>Coenzyme Q10</td>
</tr>
<tr>
<td class="label">15</td>
<td>Ambroxol (GCase chaperone)</td>
</tr>
<tr>
<td class="label">16</td>
<td>Omega-3 fatty acids (DHA/EPA)</td>
</tr>
<tr>
<td class="label">17</td>
<td>Sleep optimization/apnea treatment</td>
</tr>
<tr>
<td class="label">18</td>
<td>NACET</td>
</tr>
<tr>
<td class="label">19</td>
<td>Sulforaphane/Nrf2 activation</td>
</tr>
<tr>
<td class="label">20</td>
<td>Deferiprone (iron chelation)</td>
</tr>
<tr>
<td class="label">Symptom</td>
<td>First-Line</td>
</tr>
<tr>
<td class="label">Motor/Bradykinesia</td>
<td>Levodopa (trial)</td>
</tr>
<tr>
<td class="label">Falls/Postural instability</td>
<td>Physical therapy</td>
</tr>
<tr>
<td class="label">Neck dystonia (retrocollis)</td>
<td>Botulinum toxin</td>
</tr>
<tr>
<td class="label">Depression</td>
<td>SSRIs</td>
</tr>
<tr>
<td class="label">Apathy</td>
<td>Methylphenidate</td>
</tr>
<tr>
<td class="label">Pseudobulbar affect</td>
<td>Dextromethorphan/quinidine</td>
</tr>
<tr>
<td class="label">Rank</td>
<td>Treatment</td>
</tr>
<tr>
<td class="label">1</td>
<td>Structured exercise (aerobic + resistance + balance)</td>
</tr>
<tr>
<td class="label">2</td>
<td>Mediterranean/MIND diet</td>
</tr>
<tr>
<td class="label">3</td>
<td>Multidisciplinary rehabilitation (PT/OT/SLP)</td>
</tr>
<tr>
<td class="label">4</td>
<td>Rasagiline (MAO-B inhibitor)</td>
</tr>
<tr>
<td class="label">5</td>
<td>Rapamycin (mTOR inhibition)</td>
</tr>
<tr>
<td class="label">6</td>
<td>TUDCA/UDCA (bile acid therapy)</td>
</tr>
<tr>
<td class="label">7</td>
<td>Vitamin D supplementation</td>
</tr>
<tr>
<td class="label">8</td>
<td>Spermidine (autophagy induction)</td>
</tr>
<tr>
<td class="label">9</td>
<td>Photobiomodulation (PBM)</td>
</tr>
<tr>
<td class="label">10</td>
<td>Cognitive reserve/mental engagement</td>
</tr>
<tr>
<td class="label">Symptom</td>
<td>First-Line</td>
</tr>
<tr>
<td class="label">Motor symptoms</td>
<td>Levodopa trial</td>
</tr>
<tr>
<td class="label">Dystonia</td>
<td>Botulinum toxin</td>
</tr>
<tr>
<td class="label">Myoclonus</td>
<td>Levetiracetam, clonazepam</td>
</tr>
<tr>
<td class="label">Cognitive impairment</td>
<td>Donepezil, rivastigmine</td>
</tr>
<tr>
<td class="label">Apathy</td>
<td>Methylphenidate</td>
</tr>
<tr>
<td class="label">Depression/Anxiety</td>
<td>SSRIs</td>
</tr>
<tr>
<td class="label">Treatment</td>
<td>Efficacy</td>
</tr>
<tr>
<td class="label">[Donepezil](/entities/donepezil)</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">[Rivastigmine](/entities/rivastigmine)</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Memantine</td>
<td>Modest</td>
</tr>
<tr>
<td class="label">Aducanumab</td>
<td>Variable</td>
</tr>
<tr>
<td class="label">Treatment</td>
<td>Efficacy</td>
</tr>
<tr>
<td class="label">Carbidopa/levodopa</td>
<td>High</td>
</tr>
<tr>
<td class="label">Dopamine agonists</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">MAO-B inhibitors</td>
<td>Modest</td>
</tr>
<tr>
<td class="label">Deep brain stimulation</td>
<td>High</td>
</tr>
<tr>
<td class="label">Priority</td>
<td>Disease</td>
</tr>
<tr>
<td class="label">High</td>
<td>Parkinson's</td>
</tr>
<tr>
<td class="label">High</td>
<td>Parkinson's</td>
</tr>
<tr>
<td class="label">High</td>
<td>Parkinson's</td>
</tr>
<tr>
<td class="label">High</td>
<td>Parkinson's</td>
</tr>
<tr>
<td class="label">High</td>
<td>FTD</td>
</tr>
<tr>
<td class="label">High</td>
<td>CBS</td>
</tr>
<tr>
<td class="label">High</td>
<td>PSP</td>
</tr>
<tr>
<td class="label">Treatment</td>
<td>Current Words</td>
</tr>
<tr>
<td class="label">Ropinirole</td>
<td>6289</td>
</tr>
<tr>
<td class="label">Rotigotine</td>
<td>6620</td>
</tr>
<tr>
<td class="label">Entacapone</td>
<td>6231</td>
</tr>
</table>

Treatment Efficacy Rankings is a therapeutic approach or intervention being investigated for neurodegenerative diseases. This page reviews the scientific rationale, preclinical and clinical evidence, dosing considerations, and current status of research. [@neurowiki]

Rankings of treatments by clinical efficacy, disease modification evidence, safety profile, and clinical utility across neurodegenerative diseases.

Alzheimer's Disease Treatments

Disease-Modifying Therapies (DMTs)

Symptomatic Therapies

Parkinson's Disease Treatments

Motor Symptoms

Disease-Modifying Candidates

ALS Treatments

Huntington's Disease

Progressive Supranuclear Palsy (PSP) Treatments

PSP is a 4R-tauopathy with no FDA-approved disease-modifying therapies. Treatment focuses on symptomatic management, neuroprotection, and rehabilitation. See the [PSP Treatment](/therapeutics/progressive-supranuclear-psp-psp-treatment) page for detailed protocols and the [CBS/PSP Treatment Rankings](/therapeutics/cbs-psp-treatment-rankings) for evidence-scored interventions.

Tier 1: Strong Evidence Interventions

Tier 2: Moderate Evidence

Key Symptomatic Treatments

Emerging Disease-Modifying Approaches

Tideglusib (GSK-3β inhibitor): Phase 2 completed[^39]
Rapamycin: mTOR inhibition for autophagy
ApoE-targeted therapies: Genetic subset considerations

Corticobasal Syndrome (CBS) Treatments

CBS presents unique challenges due to heterogeneous pathology. Like PSP, no disease-modifying therapies exist. Treatment is symptomatic and rehabilitative. See the [CBS Treatment](/therapeutics/corticobasal-cbs-treatment) page for detailed protocols.

Tier 1: Strong Evidence Interventions

Key Symptomatic Treatments

Disease-Modifying Pipeline

Tau immunotherapies: Gantenerumab, semorinemab (failed in CBS)
Tideglusib: GSK-3β inhibitor (Phase 2)[^39]
Lithium: Low-dose (Phase 2)[^30]

Efficacy Metrics

Clinical Outcome Measures

ADAS-Cog: Alzheimer's cognition (0-70)
MDS-UPDRS: Parkinson's motor (0-132)
ALSFRS-R: ALS function (0-48)
UHDRS: Huntington's (0-400)

Biomarker Correlates

Amyloid PET SUVr reduction
CSF p-[tau](/proteins/tau)/t-tau ratio
Volumetric MRI loss rate

Safety Rankings

Best Tolerability

[Memantine](/therapeutics/memantine) — Minimal side effects

[Donepezil](/therapeutics/donepezil) — Generally well-tolerated

[Rasagiline](/therapeutics/rasagiline) — Once-daily

Notable Safety Concerns

ARIA (brain edema/hemorrhage): Aducanumab, [Lecanemab](/entities/lecanemab), [Donanemab](/entities/donanemab)
Liver toxicity: Many Phase 1 compounds
Cardiac: Some dopamine agonists

Symptomatic Treatment Rankings

Cognitive Symptoms

Motor Symptoms (PD)

Disease-Modifying Therapy Rankings

By Mechanism Validation

Amyloid removal: Lecanemab > Aducanumab > Donanemab

Tau targeting: Semorinemab (mixed results), tilavonemab (failed)

[Alpha-synuclein](/proteins/alpha-synuclein): Cinamerisen (ongoing trials)

Neuroinflammation: [TREM2](/proteins/trem2) agonists (early stage)

By Development Progress

Advanced (Phase 3+): Lecanemab, Donanemab, Inosine
Mid-stage (Phase 2): TREM2 agonists, gene therapies
Early (Phase 1): Novel small molecules, cell therapies

[Treatment Pipeline Overview](/treatment-pipeline-overview)
[Drug Target Landscape](/drug-target-landscape)
[Protein Drug Targets](/proteins/protein-drug-targets)
[Therapeutic Targetability](/mechanisms/_therapeutic-targets)

This page is auto-maintained. Last updated: 2026-03-15

Coverage Gaps and Needs Work

This section identifies missing or underdeveloped treatment pages that need coverage.

Critical Treatment Gaps

The following treatments have no dedicated pages but are important for neurodegenerative disease management:

Underdeveloped Existing Pages

Some treatment pages exist but need expansion:

Task Recommendations

Based on this analysis, the following tasks should be created:

Create Carbidopa treatment page — Levodopa companion drug, essential for PD treatment

Create Opicapone treatment page — Third-generation COMT inhibitor

Create Inosine treatment page — Phase 3 disease-modifying candidate for PD

Create FTD/CBS/PSP treatment overview pages — These tauopathies lack treatment coverage

Treatment Efficacy Rankings

Treatment Efficacy Rankings

Overview

Treatment Efficacy Rankings

Overview

Alzheimer's Disease Treatments

Disease-Modifying Therapies (DMTs)

Symptomatic Therapies

Parkinson's Disease Treatments

Motor Symptoms

Disease-Modifying Candidates

ALS Treatments

Huntington's Disease

Progressive Supranuclear Palsy (PSP) Treatments

Tier 1: Strong Evidence Interventions

Tier 2: Moderate Evidence

Key Symptomatic Treatments

Emerging Disease-Modifying Approaches

Corticobasal Syndrome (CBS) Treatments

Tier 1: Strong Evidence Interventions

Key Symptomatic Treatments

Disease-Modifying Pipeline

Efficacy Metrics

Clinical Outcome Measures

Biomarker Correlates

Safety Rankings

Best Tolerability

Notable Safety Concerns

Symptomatic Treatment Rankings

Cognitive Symptoms

Motor Symptoms (PD)

Disease-Modifying Therapy Rankings

By Mechanism Validation

By Development Progress

Related Pages

Coverage Gaps and Needs Work

Critical Treatment Gaps

Underdeveloped Existing Pages

Task Recommendations

See Also